Recent developments in the management of peripheral artery disease have been momentous, and a key advance has been the introduction of drug-coated balloons, which capitalise on the mechanical effects of angioplasty balloons, and on the pharmacologic effects of anti-restenotic drugs [1,2]. Indeed, single reports from randomized trials and pooled estimates from meta-analyses have clearly showed that paclitaxel-coated balloons reduce the risk of restenosis and repeat revascularization, while improving patency, limb salvage, and freedom from claudication.
Paclitaxel in endovascular devices. Identikit of a “serial killer”? / Biondi-Zoccai, G.; Frati, G.; Giordano, A.; Versaci, F.. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - 16:(2019), pp. 8-9. [10.1016/j.eclinm.2019.10.006]
Paclitaxel in endovascular devices. Identikit of a “serial killer”?
Biondi-Zoccai G.
;Frati G.;
2019
Abstract
Recent developments in the management of peripheral artery disease have been momentous, and a key advance has been the introduction of drug-coated balloons, which capitalise on the mechanical effects of angioplasty balloons, and on the pharmacologic effects of anti-restenotic drugs [1,2]. Indeed, single reports from randomized trials and pooled estimates from meta-analyses have clearly showed that paclitaxel-coated balloons reduce the risk of restenosis and repeat revascularization, while improving patency, limb salvage, and freedom from claudication.| File | Dimensione | Formato | |
|---|---|---|---|
|
Biondi-Zoccai_Paclitaxel_2019.pdf
accesso aperto
Note: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30188-9/fulltext
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
220.99 kB
Formato
Adobe PDF
|
220.99 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
